Log In
Print
BCIQ
Print
Print this Print this
 

sifalimumab (MEDI-545) (formerly MDX-1103)

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionHuman mAb targeting interferon (IFN) alpha
Molecular Target Interferon (IFN) alpha
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationLupus
Indication DetailsTreat systemic lupus erythematosus (SLE)
Regulatory Designation

Partner

AstraZeneca plc


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today